Marija Bosnjak Pasic - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Marija Bosnjak Pasic

Showing results (1-10 of 3) with videos related to

Pageof 1

Sort By:

Psychiatria Danubina|September 30, 2018

Clinical trials in developing countries - ethical considerationsMarija Bosnjak Pasic, Branka Vidrih, Helena Sarac, et al.

Multiple Sclerosis and Related Disorders|February 7, 2020

Satisfaction and adherence with glatiramer acetate 40mg/mL TIW in RRMS after 12 months, and the effect of switching from 20mg/mL QDGary Cutter, Antonella Veneziano, Augusto Grinspan, et al.

Multiple Sclerosis and Related Disorders|May 28, 2019

Higher satisfaction and adherence with glatiramer acetate 40 mg/mL TIW vs 20 mg/mL QD in RRMSGary Cutter, Antonella Veneziano, Augusto Grinspan, et al.

Pageof 1

Search research articles

Showing results (1-10 of 3) with videos related to

Sort By:

Pageof 1

Psychiatria Danubina|September 30, 2018

Clinical trials in developing countries - ethical considerationsMarija Bosnjak Pasic, Branka Vidrih, Helena Sarac, et al.

Multiple Sclerosis and Related Disorders|February 7, 2020

Satisfaction and adherence with glatiramer acetate 40mg/mL TIW in RRMS after 12 months, and the effect of switching from 20mg/mL QDGary Cutter, Antonella Veneziano, Augusto Grinspan, et al.

Multiple Sclerosis and Related Disorders|May 28, 2019

Higher satisfaction and adherence with glatiramer acetate 40 mg/mL TIW vs 20 mg/mL QD in RRMSGary Cutter, Antonella Veneziano, Augusto Grinspan, et al.

Pageof 1